Eculizumab in AQP4-IgG NMOSD
Efficacy in the Real World and Potential Warning of Meningococcal Vaccines
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-625.
2.
Ringelstein M, Asseyer S, Lindenblatt G, et al. Eculizumab use in neuromyelitis optica spectrum disorders: routine clinical care data from a European cohort. Neurology. 2024;103(9):e209888.
3.
Wingerchuk DM, Fujihara K, Palace J, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088-1098.
4.
Paul F, Marignier R, Palace J, et al. International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124.
5.
Langer-Gould A, Li BH, Smith JB, Xu S. Multiple Sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200211.
6.
Anamnart C, Tisavipat N, Owattanapanich W, et al. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review. Mult Scler Relat Disord. 2022;58:103414.
7.
Kanduc D. Molecular mimicry between meningococcal B factor H-binding protein and human proteins. Glob Med Genet. 2023;10(4):311-314.
8.
Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection—serum bactericidal antibody activity. Vaccine. 2005;23(17-18):2222-2227.
Information & Authors
Information
Published In
Copyright
© 2024 American Academy of Neurology.
Publication History
Received: July 18, 2024
Accepted: August 20, 2024
Published online: October 1, 2024
Published in print: November 12, 2024
Disclosure
R. Marignier serves on scientific advisory boards for Alexion, Roche, and UCB, and has received honoraria from Alexion, Biogen, and Roche. A. Kunchok reports no relevant disclosures. Go to Neurology.org/N for full disclosures.
Study Funding
The authors report no targeted funding.
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.